...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Assessment of target dose delivery in anal cancer using in vivo thermoluminescent dosimetry.
【24h】

Assessment of target dose delivery in anal cancer using in vivo thermoluminescent dosimetry.

机译：使用体内热发光剂量法评估肛门癌中的目标剂量递送。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To measure anal dose during external beam radiotherapy (EBRT) using in vivo dosimetry, to study the difference of measured from prescribed dose values, and to evaluate possible associations of such differences with acute and late skin/mucosal toxicity and anorectal function. MATERIALS: Thirty-one patients with localized anal carcinoma underwent in vivo measurements during the first EBRT session. Themoluminescent dosimeters (TLD) were placed at the center of the anal verge according to a localization protocol. No bolus was used. Patients received a median dose of 39.6 Gy (range: 36-45 Gy) by anteroposterior opposed AP/PA pelvic fields with 6 or 18 MV photons, followed by a median boost dose of 20 Gy (range: 13-24 Gy). Concomitant chemotherapy (CCT), consisting of 1-2 cycles of continuous infusion 5-fluorouracil (5-FU) and bolus mitomycin-C (MMC), was usually administered during the first weeks of the pelvic and boost EBRT courses. Acute and late skin/mucosal reactions were recorded according to the Radiation Therapy Oncology Group (RTOG) toxicity scale. Anal sphincter function was assessed using the Memorial Sloan Kettering Cancer Center (MSKCC) scale. RESULTS: TLD anal doses differed by a mean of 5.8% (SD: 5.8) in comparison to the central axis prescribed dose. Differences of at least 10% and at least 15% were observed in eight (26%) and three (9.7%) patients, respectively. TLD doses did not significantly correlate with acute or late grade 2-3 skin or mucosal toxicity. However, patients having good-fair MSKCC anal function had a significantly greater mean difference in anal TLD dose (10.5%, SD: 5.9) than patients having excellent function (3.8%, SD: 4.6) (P = 0.004). Prescribed dose values, length of follow-up, and age at diagnosis did not correlate with late sphincter function. CONCLUSIONS: These data show that AP/PA fields using megavoltage photons deliver adequate dose to the anal verge. However, in about one quarter of patients treated with this technique the anal dose varied from the prescribed dose by at least 10%. The observed correlation of TLD values and late sphincter function suggests that direct measurement of the dose delivered to the anal verge might be clinically relevant.
机译：目的：使用体内剂量测定法在体外放射治疗（EBRT）期间测量肛门剂量，研究所测量剂量与规定剂量值之间的差异，并评估这种差异与急性和晚期皮肤/粘膜毒性及肛门直肠功能的可能联系。材料：31例局限性肛门癌患者在第一次EBRT期间接受了体内测量。根据定位协议，将发光剂量计（TLD）放置在肛门边缘的中央。不使用大丸剂。患者通过具有6或18个MV光子的前后对侧AP / PA骨盆区域接受39.6 Gy（范围：36-45 Gy）的中值剂量，然后接受20 Gy（范围：13-24 Gy）的中值加强剂量。伴随化疗（CCT），包括1-2个周期的连续输注5-氟尿嘧啶（5-FU）和推注丝裂霉素C（MMC），通常在盆腔和加强EBRT疗程的最初几周内进行。根据放射治疗肿瘤学组（RTOG）毒性等级记录急性和晚期皮肤/粘膜反应。使用纪念斯隆凯特琳癌症中心（MSKCC）量表评估肛门括约肌功能。结果：与中心轴处方剂量相比，TLD肛门剂量平均相差5.8％（SD：5.8）。分别在八名（26％）和三名（9.7％）患者中观察到至少10％和至少15％的差异。 TLD剂量与2-3级急性或晚期皮肤或粘膜毒性没有显着相关性。然而，具有良好MSKCC肛门功能的患者的肛门TLD剂量的平均差异（10.5％，SD：5.9）明显高于具有优异功能的患者（3.8％，SD：4.6）（P = 0.004）。规定的剂量值，随访时间和诊断时的年龄与括约肌晚期功能无关。结论：这些数据表明，使用兆伏光子的AP / PA场可向肛门边缘提供足够的剂量。但是，在接受这种技术治疗的患者中，约四分之一的肛门剂量与处方剂量相差至少10％。观察到的TLD值与晚期括约肌功能之间的相关性表明，直接测量递送至肛门边缘的剂量可能与临床相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号